(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
UN estimates over 2,000 Sudanese pregnant women have fled el-Fasher to escape conflict - 2Volcanic eruption led to the Black Death, new research suggests
- 36 Famous kind of practice on the planet
- 4Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- 5The moon and sun figure big in the new year's lineup of cosmic wonders
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Find the Abilities Required for Advanced Advertising Position
- Finding Ideal Date Spots for Two or three Encounters
- Vote in favor of Your Fantasy Vehicle: Which Notable Model Catches Your Heart?
- 10 Hints and Deceives to Expand Cell Phone Information Use: Capitalize on Your Information
- 5 Christmas movies to stream for less with this Paramount+ Black Friday deal
- Ocean side Objections: Staggering Waterfront Breaks
- Which European countries have mandatory or voluntary military service
- Manual for Tracking down One of a kind Store Inns
